This biotechnology company is focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industries.
1 Like
The opportunity in this one now is phenomenal.
Fully funded at 20p which was a premium fundraise. Crispin Odey - 18% holding recently acquired.
Stephen Diggle - billionaire asset manager, non executive director with 13% holding via Vulpes.
CiRT Episwitch blood test to predict how patients eligible for immunotherapy cancer treatment will respond.
Only around 12% of patients will respond to treatment. This test is a simple blood test and far less invasive than other methods.
But not just the fact it’s a simple blood test… the savings it will have are a major selling point…
“In terms of the healthcare economics, ICIs alone cost the US healthcare system $17B annually. The ability to stratify patients based on their likelihood of response will enable the system to better manage these costs while allowing us to deliver smarter, better care to patients.”
Product is ready launched. No trial. Big push coming with oncologists presenting to major co’s via ESMO etc.
Capacity for 10,000 tests at $1500 to $3500
2 million cancer cases in USA each year, around 40% eligible for immunotherapy treatments but only 12% will respond- do the maths on numbers.
Then you’ll see why Odey took 18% of co.
Note the news recently it can now be eligible for reimbursements on us health care plans (see RNS)… they raised cash just after that and the big money all piled in.
Worth looking at while it’s at this price with a few month view!!
EpiSwitch(R) CiRT is a blood-based predictive test of a patient’s likely response to checkpoint inhibitor (ICI) therapies, offering valuable insight for oncologists, their patients and healthcare systems alike.
In 2019, in the US, approximately $14bn was spent on checkpoint inhibitor therapies, with 300,000 patients receiving treatment with these drugs. However, on average fewer than one third of such patients are likely to benefit from treatment with ICIs. A significant proportion will experience an adverse reaction to the therapy, but some of these will see a clinical benefit if they continue after being treated for the reaction. As such, knowing the likelihood of response can assist doctors in deciding on the appropriate course of treatment, including for patients who show significant adverse reactions but who should be treated and encouraged to continue with ICI therapies.
The Group launched its flagship product, the EpiSwitch(R)CiRT in February 2022, initially in the US, adding availability to private physicians in the UK in June 2022.
The Company is now poised to expand the sales group to capitalize on these early learnings and drive market penetration and traction of CiRT in multiple US geographies.
From 1 October 2022, reimbursement claims for CiRT will be submitted to payors using the unique PLA Code for the test that was published by the American Medical Association’s CPT (Current Procedural Terminology) Editorial Board on 1 July 2022.
1 Like
So right now they’re awaiting first big sales push from USA. They signed an agreement with a top 10 pharma at ASCO, but this was before they got the full reimbursement code so the tests can be claimed via health insurance.
Here’s the push so far… next news could be sales and away we go…
ASCO went well for CiRT.
“Interest in CiRT at ASCO was significant; OBD representatives held positive meetings with 11 pharma teams, two major US hospital networks , National Cancer Institute-designated comprehensive cancer centers, as well as with clinicians and healthcare investors.”
“Early uptake of EpiSwitch CiRT has been encouraging, as have recent developments such as the signing of a master service agreement with a top-10 pharma company.”
Then they presented at ESMO
“The ESMO Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.”
Upcoming…
EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit
“The 2022 PMLS Liquid Biopsy Virtual Summit will gather key opinion leaders in the liquid biopsy field to discuss their experiences in implementing these tests in the clinical setting.”
“Attendees will include oncologists, pathologists, clinical lab managers, executives and decision makers at hospital and health care systems, regulatory leaders in government and business affairs groups, test developers, and more.”
Grim statistics but… 2 million Americans diagnosed cancer each year. Around 43% of them are eligible candidates for immunotherapy treatments.
BUT… only 12% of that 43% will actually respond to the treatment. And in many cases some who don’t respond get really ill.
That’s potentially over 800,000 people that could benefit from this test yearly.
**If OBD even caught 5% of this market size it would be 40,000 people. **
The tests are $1500 to $3000
I’ll let you do maths on this. But you can see why billionaire Steven Diggle and Crispin Odey have been buying here.
Im not sure if I’m allowed to post Youtube links but…
If you have a few minutes, watch from here 37 minutes into summer webinar.
“Huge things on the Horizon” First deals from MSA to land soon. Multi million pound deals, 6 big pharma names all at stage of contract signing…
The time is now… this was a few month back!
Investec added to holding I see. Insti’s loading up!
An excellent tweet thread and summary of webinar here. Worth taking note!
Being presented by a leading oncologist at liquid biopsy summit today… to all big players in healthcare… be tucking a few away, these are on the edge of revenue generating here and the market is massive
Revenue updates soon. Do your research
RNS. A new test being developed on their Episwitch platform. Interesting
“identify biomarkers that could serve as quantifiable, biological and non-clinical measures of Edaravone’s pharmacodynamic effect in ALS”
Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis.
“ We are delighted with the initial interim results reported about the use of EpiSwitch in the REFINE-ALS trial. Robust clinical biomarkers based on liquid biopsy have been long predicted to change the practice of medicine, and if proven, could become part of medical standards in XXI century."
Another big market for a second test.
CiRT is (their ready for revenue cancer ICI test) already a commercial test
Big markets
Hope you all picked some up. The prostate cancer test is huge news. In daily mail today
And ITV
This could go nuts. The NHS might be forced to look into this test with the high accuracy and national coverage, prostate cancer testing is absolutely mammoth market size.
Nobody interested here? You only got to look at GDR and see what a test that the NHS decide to adopt can do. 3 bagged on speculation leading up to todays rns. They may be forced to move deeper into this after all the press here, ITV news, Radio 4, Independent, Daily Mail. Fingers crossed.
Anywhere where i can read what they have planned for 2023 carnt see nothing anywhere
Here’s the webinar released after full year results a few week ago
Anyone notice the pop up on the website when you visit now? Sounds like they’ve been inundated with queries about the prostate cancer test since ITV news etc (above links)
I can see this being hurried through testing or getting a partner to fast track it. I mean 94% accuracy and non invasive blood test? compared to biopsy >>
“Only about a quarter of people who have a prostate biopsy due to an elevated PSA level are found to have prostate cancer.
“There has therefore been a drive to create a new blood test with greater accuracy.”
On website >>
Thanks looks like the start of something good